Provectus Pharmaceuticals Inc. PVCT Archives

WednesdayNov 28, 2007 4:43 am

Provectus Pharmaceuticals, Inc. (PVCT.OB) Rated Market Perform Rating

Rodman & Renshaw, LLC, a leading investment bank, initiated research coverage of Provectus Pharmaceuticals, Inc. (PVCT) by granting the company a Market Perform Rating. Provectus Pharmaceuticals, a leading Pharmaceutical company, specializes in developing oncology and dermatology therapies that are safer, more effective, and less invasive than current therapies. Currently, Provectus is conducting Phase 2 clinical trials of two of their proprietary drugs, PV-10 and PH-10. PV-10 is used as to treat melanoma and breast cancer, and PH-10 as a topical treatment for moderate to severe psoriasis. The Company has already received orphan drug designation from the FDA for metastatic melanoma.…

TuesdayNov 27, 2007 5:22 am

Provectus Pharmaceuticals, Inc. (PVCT.OB) Treats First Patient with Topical PH-10 at Mount Sinai School of Medicine

Provectus announced today that it has begun treating its first patient and is recruiting patients for the Phase 2 clinical trial of topical PH-10, which is designed to treat psoriasis. The study will assess the effectiveness of topically applied PH-10 in twenty-five participants. The medication will be administered twice a week for up to twelve weeks. The entire study is taking place at the Mount Sinai School of Medicine in New York and is anticipated to take nine months to complete. Craig Dees, Ph.D., CEO of Provectus, stated, “We are pleased to offer patients with moderate to severe psoriasis the…

TuesdayNov 13, 2007 5:33 am

Provectus Pharmaceuticals, Inc. (PVCT.OB) Commences Phase 2 Clinical Trial

Provectus Pharmaceuticals announced today that it has received approval to begin Phase 2 clinical testing of PH-10, the company’s topical drug designed to treat psoriasis. The study is intended to identify the effectiveness of PH-10 by using twenty-five subjects with moderate to severe forms of the disease. PH-10 will be applied twice weekly for up to twelve weeks to each participant’s psoriatic plaque areas. The reaction will be monitored throughout this treatment phase and a month after the end of the phase. Response will be graded using the Psoriasis Severity Index (PSI) and an investigator’s clinical assessment of Plaque Response. Changes…

MondayNov 05, 2007 6:57 am

Provectus Pharmaceuticals, Inc. (PVCT.OB) is “One to Watch”

Provectus Pharmaceuticals is focused on developing advanced therapies designed to target and destroy the deadliest cancer as well as developing groundbreaking biotechnologies to augment vaccine production and detect viruses. The company is currently conducting clinical trials on their two proprietary drugs, Provecta and Xantryl. Provectra is unique from other cancer treatments by concentrating on toxic levels of tissue while avoiding healthy tissue consequently making it safer and more effective than conventional therapies such as chemotherapy and radiation. The drug is targeting melanoma and focal tumors of the breast, liver and prostate, which together account for more than 520,000 new cases…

Site Search

Company Search

Tag: Provectus Pharmaceuticals Inc. PVCT

Provectus Pharmaceuticals, Inc. (PVCT.OB) Rated Market Perform Rating

Provectus Pharmaceuticals, Inc. (PVCT.OB) Treats First Patient with Topical PH-10 at Mount Sinai School of Medicine

Provectus Pharmaceuticals, Inc. (PVCT.OB) Commences Phase 2 Clinical Trial

Provectus Pharmaceuticals, Inc. (PVCT.OB) is “One to Watch”

Market Basics

Newsletter Publishers

Public Companies